Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...